MYO Myomo Inc.

Myomo Inc.

Industrial Specialties

Health Care

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

IPO Year: 2017

Exchange: AMEX

Website: myomo.com

Recent Analyst Ratings for Myomo Inc.

Date	Price Target	Rating	Analyst
7/31/2024	$7.00	Buy	Craig Hallum
5/20/2024	$7.00	Buy	Lake Street
12/15/2023	$6.50	Buy	H.C. Wainwright

See more ratings

Myomo Inc.

Recent Analyst Ratings for Myomo Inc.

Myomo Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Kovelman Harry was granted 62,938 shares, increasing direct ownership by 69% to 153,672 units (SEC Form 4)

Chief Commercial Officer Mitchell Micah was granted 59,440 shares, increasing direct ownership by 42% to 199,709 units (SEC Form 4)

Chief Financial Officer Henry David A was granted 76,398 shares, increasing direct ownership by 20% to 451,487 units (SEC Form 4)

Chief Executive Officer Gudonis Paul R was granted 157,342 shares, increasing direct ownership by 15% to 1,209,013 units (SEC Form 4)

Director Kirk Thomas F was granted 29,720 shares, increasing direct ownership by 9% to 374,420 units (SEC Form 4)

Director Crowley Thomas Aloysius Jr. was granted 29,720 shares, increasing direct ownership by 71% to 71,748 units (SEC Form 4)

Director Morris Milton Mayo was granted 29,720 shares, increasing direct ownership by 26% to 144,687 units (SEC Form 4)

Director Getz Heather C was granted 29,720 shares, increasing direct ownership by 247% to 41,754 units (SEC Form 4)

Chief Medical Officer Kovelman Harry covered exercise/tax liability with 5,743 shares, decreasing direct ownership by 6% to 90,734 units (SEC Form 4)

Chief Financial Officer Henry David A covered exercise/tax liability with 8,373 shares, decreasing direct ownership by 2% to 375,089 units (SEC Form 4)